<DOC>
	<DOCNO>NCT00421538</DOCNO>
	<brief_summary>CACTUS-PTS randomize , placebo-controlled , double-blind study aim primarily determine effectiveness 6 week course therapeutic-dose LMWH ( nadroparine ) injection vs. placebo patient first symptomatic isolate distal ( calf ) deep-vein thrombosis ( IDDVT ) , measure rate proximal DVT symptomatic PE 6 week . Additionally , study aim determine 6 week course treatment therapeutic-dose LMWH ( nadroparine ) injection , compare placebo , decrease frequency post-thrombotic syndrome ( PTS ) 1 year .</brief_summary>
	<brief_title>Randomized Controlled Trial Anticoagulation v . Placebo First Symptomatic Isolated Distal Deep-vein Thrombosis ( IDDVT )</brief_title>
	<detailed_description>The CACTUS-PTS study compare anticoagulant treatment 6 week versus placebo acute , symptomatic distal DVT . Patients randomize receive either six-week period LMWH therapeutic dosage six-week period placebo . All patient treat elastic compression stocking followed-up standardized ultrasonography protocol . Strict ultrasonographic diagnostic criterion distal DVT define . Control compression ultrasonography perform day 3 7 six week inclusion . The primary outcome composite proportion patient extension thrombus proximal vein ( detect program ultrasound examination ultrasound perform recurrent symptom ) symptomatic PE arm study 6-weeks study period . Patients outcome anticoagulated currently admit presence proximal DVT . Secondary outcome individual component composite endpoint ( distal DVT extension proximal vein ; symptomatic PE ) , major bleeding , serious adverse event death report 6 week 90 day . To answer research question PTS add-on study , patient self-assess assessed PTS clinician use Villalta scale , 1 year follow enrolment trial . In addition , patient complete Quality Life ( QOL ) questionnaire . The QOL questionnaire comprise VEINES-QOL SF-36 . The primary outcome rate PTS , secondary outcome QOL score PTS severity .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<criteria>All outpatient acute , symptomatic , distal DVT include study , provide correspond follow diagnostic exclusion criterion , sign informed consent form . Age le 18 year Previously objectively diagnosed DVT PE Distal DVT involve tibioperoneal trunk ( i.e . calf trifurcation ) Clinically suspect pulmonary embolism Active cancer , receive cancer treatment cancer consider cure &lt; 6 month Ipsilateral contralateral proximal DVT Indication longterm anticoagulation ( e.g . atrial fibrillation , mechanical heart valve ... ) Pregnancy Thrombocytopenia ( platelet count &lt; 100 g/l ) Impaired renal function ( serum creatinine &gt; 180 micromol/l clearance creatinine le 30 ml/min ) Known hypersensitivity heparin Presence active bleeding pathology susceptible bleed presence anticoagulation ( gastric ulcer , cerebral malignant disease ... ) Treatment daily NSAIDs ( aspirin â‰¤160 mg/day permit ) Body weight &gt; 115 kg &lt; 40 kg Treatment therapeutic dos anticoagulant &gt; 2 day , correspond : 2 injection LMWH daily therapeutic LMWH use ; 3 injection LMWH twicedaily therapeutic LMWH use ; 1 dose oral vitamin K antagonist ( e.g . warfarin ) Ongoing requirement prophylactic dose thromboprophylaxis ( e.g . acute postop patient receive thromboprophylaxis ) Enrolled another clinical trial within previous 30 day Inability refusal provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Deep vein Thrombosis</keyword>
	<keyword>Calf vein thrombosis</keyword>
	<keyword>Low-molecular weight heparin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Elastic contention</keyword>
	<keyword>Compression Ultrasonography</keyword>
</DOC>